GlassScriptPhysician profile
David Young Yoo
NPI 1093178410
$11,216.65
in general payments reported to CMS, 2019-2025
25 companies · $3,012 in 2025
The $3,012 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $986 · 2020: $1,106 · 2021: $1,013 · 2022: $1,177 · 2023: $1,813 · 2024: $2,109 · 2025: $3,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,790 · Entertainment: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,789.61 |
| Entertainment | $144.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $2,640.83 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $1,175.43 | 2022-2025 | Infuse, Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $897.82 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $889.08 | 2019-2025 | Eysuvis, Tryptyr, Clareon Panoptix Pro |
| Dompe US, INC. | $676.14 | 2024-2025 | Oxervate |
| Coopervision INC. | $657.36 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Onefit Contact Lens |
| Biotissue Holdings INC. | $597.61 | 2020-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $559.36 | 2019-2021 | |
| Oyster Point Pharma, INC. | $531.73 | 2022-2025 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $481.79 | 2020-2021 | |
| Visioneering Technologies, INC. | $465.19 | 2019-2025 | |
| Glaukos Corporation | $230.40 | 2020-2022 | |
| Sight Sciences, INC. | $223.97 | 2020-2024 | Tearcare System |
| Optos, INC. | $211.65 | 2022-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $191.83 | 2024-2025 | Xdemvy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $140.69 | 2023-2025 | Iyuzeh |
| Harrow Eye, LLC | $138.69 | 2024-2025 | Vevye, Natacyn |
| Maculogix, INC. | $130.66 | 2020 | |
| Kala Pharmaceuticals, INC. | $120.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $85.91 | 2022-2023 | |
| Shire North American Group INC | $70.31 | 2019 | |
| Lumenis, INC | $28.88 | 2021 | |
| Oasis Medical, INC. | $26.94 | 2025 | Oasis Tears |
| Amgen INC. | $22.08 | 2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $21.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.